Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 3/29/23 → 3/28/26 |
Funding
- Exelixis Inc.: $159,668.00
22-GI-129-EI: XL092-303, A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
- Patel, Reema (PI)